Pharmacist support may boost rheumatoid arthritis treatment — a trial puts it to the test
NCT ID NCT07726355
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial tests whether adding a clinical pharmacist to standard drug therapy helps people with early rheumatoid arthritis achieve better disease control. Participants receive pharmacist-led education, counseling, and medication management alongside their usual DMARD treatment. The study aims to see if this combined approach improves disease activity, medication adherence, and quality of life compared to standard care alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- clinical pharmacist-led education and counseling alongside standard DMARD therapy
- What this could lead to
- If it works, this could point toward a more effective care model for early rheumatoid arthritis that combines medication with pharmacist support to improve disease control and quality of life.
- What could go wrong
- This is a small, early-phase trial, so results may not apply broadly. The benefit of pharmacist intervention over standard care alone remains unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assiut university
Minya, Egypt